Variations in outcome of patients from different geographic regions have been observed in many large international trials. We analysed the factors that might contribute to the geographic variations in patient outcome and treatment effect as observed in the PURSUIT trial.
Results
Major differences in baseline demographics were apparent among the four regions; in particular, more patients from E. Europe had characteristics associated with impaired outcome. Interventional treatment also varied considerably, with more patients from N. America undergoing revascularization. Despite differences in the 72 h event rate, eptifibatide showed a consistent trend towards a reduction in the composite end-point among all four regions and for all definitions of infarction. Relative reductions ranged from 17-42% in W. Europe, 23-35% in N. America, 0-33% in E. Europe, and 55-82% in L. America. After multivariable adjustment, the pattern of benefit with eptifibatide was consistent among the regions. In patients undergoing percutaneous coronary intervention during study drug infusion in W. Europe (n=266) and N. America (n=931), the relative reduction in myocardial infarction during medical therapy ranged from 56-75% in W. Europe and 14-67% in N. America, while the reduction in procedure-related events ranged from 12-44% and 25-61% for different definitions of infarction. After multivariable adjustment neither benefit nor rebound were apparent after study drug discontinuation, or after 3 days in all regions, except in L. America. In general, the differences in outcome and treatment effect were greatest when the protocol definition of myocardial infarction (CK(-MB) >1 upper normal limit) was applied. Under stricter definitions, these differences became smaller and disappeared with the investigator's assessment.
Introduction
The PURSUIT trial (Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) compared the glycoprotein IIb/IIIa inhibitor eptifibatide (Integrilin , COR Therapeutics, Inc.) with placebo in addition to standard therapy in 9461 patients with acute coronary syndromes who did not have persistent-ST-segment elevation. PURSUIT is the largest trial to date in this patient population [1] . A total of 726 hospitals from 27 countries in four geographic regions (Western Europe, North America, Eastern Europe, Latin America) participated. Compared with placebo, treatment with eptifibatide resulted in a significant 1·5% absolute reduction in death or myocardial infarction at 30 days. As in other large international trials, there were considerable variations in outcome of patients in different geographic regions [1] [2] [3] [4] [5] . Due to the large number of patients treated in the various regions, this trial afforded a unique opportunity to gain insight into the heterogeneity of the disease and patient population, and to study differences in medical practice patterns and treatment strategies. Therefore, we reviewed these regional differences and analysed the factors that might contribute to the geographic variations in patient outcome and treatment effect.
Methods
The study design and results of the PURSUIT trial have been published in detail [1, 6] . Briefly, patients were eligible for enrolment if they had ischaemic chest pain within the previous 24 h and either ECG changes suggestive of ischaemia (ST-segment depression, T-wave inversion, or transient ST-segment elevation) or a creatine kinase MB fraction above the upper limit of normal for that hospital. Patients with persistent ST-segment elevation were excluded since they should be considered for immediate reperfusion therapy [7] . Patients were randomly assigned in double-blind fashion to an intravenous bolus and infusion of placebo or 180 g . kg 1 bolus plus infusion of 2·0 g . kg 1 min 1 eptifibatide. Study drug was to be infused over 72 h, but could be continued for up to 96 h if a percutaneous coronary intervention was performed at the end of the 72 h treatment period. All other treatment decisions, including the use of heparin, other anti-ischaemic medications and coronary angiography as well as the use and timing of percutaneous or surgical coronary revascularization, were left to the discretion of the treating physician. The primary end-point was the 30-day composite of death or non-fatal myocardial (re)infarction as adjudicated by an independent Clinical Events Committee blinded to treatment assignment.
Additional data analysis
Since the treatment effect at the end of the initial study drug infusion period provides the most accurate estimation of the benefit of eptifibatide as well as an even playing field for comparison of the treatment benefits of eptifibatide across the four geographic regions, treatment effects at 72 h in the study were determined. For each region separately, the incidence of the composite end-point of death or non-fatal myocardial infarction was determined with the Kaplan-Meier method during the scheduled 72 h study drug infusion period among all patients randomized, while patients were censored at the time of intervention. In patients who underwent a percutaneous coronary intervention during the first 72 h, the incidence of myocardial infarction was evaluated in the period before the intervention, while the rate of death or myocardial infarction was assessed within the first 48 h of the intervention as well as in the subsequent time window up to 30 days. In each period, only patients who were event-free at the beginning of that period were considered. Additionally, in patients who did not reach a study end-point and did not undergo a percutaneous coronary intervention during the first 72 h, the rate of the end-point between day 3 and day 30 was determined using the Kaplan-Meier estimate.
Definitions of myocardial infarction
In the assessment by the Clinical Events Committee, myocardial (re)infarction was defined by ECG abnormalities or creatine kinase(-MB) elevation [1, 6] . The definitions were specific to clinical scenarios of early or later myocardial infarctions and to infarctions associated with cardiac revascularization procedures [1, 6] . A sensitive definition of cardiac enzyme elevation was applied: a single creatine kinase-MB value elevated above the upper limit of normal was sufficient to diagnose a myocardial infarction. Following percutaneous or surgical intervention, the elevation of enzyme levels was required to be at least three or five times the upper limit of normal, respectively.
Additional analyses were performed using the investigator's determination of myocardial infarction, and the assessment by the Clinical Events Committee with application of higher thresholds of creatine kinase-MB (or, in its absence, creatine kinase) of two, three or five times the upper limit of normal. For defining a percutaneous coronary intervention-related myocardial infarction, the creatine kinase-MB was required to be above three times the upper limit of normal during the first 24 h following the intervention, while in the subsequent period up to 48 h post-percutaneous coronary intervention a creatine kinase-MB value was required which exceeded one of the pre-specified thresholds as set for the other time windows.
Statistical methods
Continuous variables are presented as medians with 25th and 75th percentiles, discrete variables as frequencies and percentages. Baseline characteristics and treatment parameters among the regions were compared univariably using the Kruskal-Wallis test for all continuous variables and Pearson's chi-square test for all incidences. Outcomes between eptifibatide and placebo patients within each region were compared univariably using Fisher's Exact Test. Statistical significance was determined to be Pc0·05. A multivariable logistic regression model was used to evaluate the relationship between geographic region and outcome for different definitions of myocardial infarction. The model was adjusted for variables found to be significant predictors of the 30-day composite of death or non-fatal myocardial infarction in the overall PURSUIT population [8] . Variables and their independent association with these outcomes are presented as odds ratios with 95% confidence intervals. Multivariable regression was also performed to determine the interaction term between region and eptifibatide treatment. Results of the multivariable regression analysis were then used to calculate the new, multivariable-adjusted odds ratios for the eptifibatide treatment effect.
Results

Baseline demographics and adjunctive therapy
A total of 9461 patients were enrolled in the placebo and the eptifibatide 180/2·0 groups of the PURSUIT study [1] . Of these, 3827 (41%) were enrolled in North America, 3697 (39%) in Western Europe, 1541 (16%) in Eastern Europe and 396 (4%) in Latin America. Major differences in baseline characteristics were apparent among these four geographic regions (Table 1 ). For example, age was highest in European patients, while in Eastern Europe more female patients were enrolled, as well as more patients with heart failure. Furthermore, patients from Eastern Europe had more severe angina preceding hospitalization, more often exhibited ST-segment depression on the qualifying electrocardiogram, and presented with a higher blood pressure. In contrast, patients from North America had a higher body weight, were more frequent diabetics, and had more frequently undergone revascularization procedures. In more patients 
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from North America the qualifying episode was classified as a myocardial infarction. Medical and interventional treatment also varied among regions, with more patients from North America receiving heparin and undergoing angiography, percutaneous coronary intervention or coronary bypass surgery (Fig. 1 ). The percentage of percutaneous coronary interventions performed during the 72-h study drug infusion period was substantially higher among patients enrolled in North America than in the other regions. In all regions, over 90% of all patients received aspirin during hospitalization. Beta-blockers were used more frequently in Western Europe, while more Eastern European patients received ACE-inhibitors, reflecting the higher rates of previous infarction and heart failure in this region. The different treatment strategies were also apparent in the duration of hospital stay which was shortest in North America (median 6 days), and twice as long in Eastern Europe (median 13 days) with intermediate figures for Western Europe and Latin America (median 10 days, both).
Early (<72 h) patient outcome and treatment effect
In the PURSUIT study, the effect of eptifibatide on reducing death or myocardial infarction was apparent at 72 h, while this treatment effect remained essentially unchanged during the subsequent 30 days [1] . At 72 h, mortality was highest among patients from Latin America followed by Eastern Europe (Table 2 ). Applying a variety of definitions of myocardial infarction, patients enrolled in Eastern Europe and Latin America had a higher rate of death or infarction than those enrolled in Western Europe and North America. As expected, the number of end-points decreased in each region when a more stringent definition of myocardial infarction was applied. By multivariable analysis, the rate of death or myocardial infarction at 72 h according to the Clinical Events Committee was related to the geographic region (Table 3) . After adjustment for differences in baseline characteristics, patients enrolled in Latin America and Eastern Europe were at a higher risk of adverse cardiac events than those from Western Europe, whereas patients treated in North America were at a lower risk. When progressively higher thresholds of enzyme elevation were used in the definition of myocardial infarction, North America and Eastern Europe were no longer statistically significant predictors of the combined outcome. In contrast, Latin America remained an independent risk factor for the occurrence of death or infarction at 72 h.
The absolute and relative reduction in the composite end-point of death or myocardial infarction after 72 h in patients receiving eptifibatide when compared with those in the placebo group appeared larger in Latin America than in the other regions for all infarct definitions (Table 2 ). This difference in treatment effect was, however, not statistically significant. Within each region separately as well as among all four geographic regions there was a remarkable consistency with respect to the directionality of the treatment effect, independent of the definition of myocardial infarction (Fig. 2) . Although the magnitude of benefit differed and did not reach statistical significance in all comparisons, a beneficial effect of eptifibatide was apparent for all definitions of myocardial infarction among all four regions. Only one exception was observed: the original assessment by the Clinical Events Committee of myocardial infarction occurring in Eastern Europe (Table 2) . After multivariable adjustment, the reduction in death or myocardial infarction at 72 h by eptifibatide did not differ significantly between Western Europe, Eastern Europe and North America when the original Clinical Events Committee adjudication was used or when a definition of myocardial infarction with thresholds of creatine kinase(-MB) of two or three times the upper limit of normal was applied (Fig. 2) . In Western Europe, a slightly greater and statistically significant treatment benefit was observed on mortality and the combined end-point with a threshold of creatine kinase(-MB) of five times the upper limit of normal or the investigator's assessment of infarction. Additionally, the odds ratios of the treatment benefit observed in Latin America were significantly lower than in the other regions when a definition of myocardial infarction of creatine kinase (-MB) exceeding two or three times the upper limit of normal was applied to the original adjudication by the Clinical Events Committee or when the investigator's assessment was used.
In patients undergoing early (i.e. within 72 h) percutaneous coronary intervention in Western Europe (n=266) or North America (n=931), there was a consistent pattern of benefit with eptifibatide during medical therapy, which was augmented by the use of eptifibatide during the intervention. Although only some 
Multivariable-adjusted odds ratios relative to Western Europe are provided with their 95% confidence interval in parentheses. Early event rate represents the 72-h, PCI-censored end-point of death or composite of death or myocardial infarction (figures shown in Table 2 ), while the late event represents the 3-30 day end-point of death or composite of death or myocardial infarction in patients with no end-point or PCI during the first 72 h (figures presented in Table 4 ). CEC=Clinical Events Committee; CEC >2, CEC >3, CEC >5=composite end-point according to the Clinical Events Committee with application of thresholds of creatine kinase(-MB) of two, three and five times the upper limit of normal in the definition of myocardial infarction, respectively; PCI=percutaneous coronary intervention. Other abbreviations, see Table 1 .
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of the differences reached statistical significance, the directionality of the benefit was again remarkably consistent and apparent for all definitions of myocardial infarction (Fig. 3) . During medical therapy preceding percutaneous coronary intervention, the relative reduction in myocardial infarction ranged from 56 to 75% in Western Europe and from 14 to 67% in North America. The rate of myocardial infarction associated with percutaneous coronary intervention was higher than in the preceding clinical treatment period. The absolute and relative treatment benefit of eptifibatide was greater in patients undergoing early percutaneous coronary intervention, both in the medical treatment period preceding the intervention and in association with the intervention, as compared with patients in whom no intervention was performed in the first 72 h. Neither additional treatment effect nor rebound were apparent after discontinuation of eptifibatide or placebo. The numbers of patients undergoing early coronary intervention in Eastern Europe (n=31) and Latin America (n=16) were too small for a meaningful analysis.
Late (3-30 days) patient outcome and treatment effect
In patients who did not reach a study end-point or undergo a percutaneous coronary intervention in the first 72 h, the subsequent incidence of the composite of death or myocardial infarction at 30 days was high (Table 4) . In contrast to the early patient outcome, geographic region was not a significant predictor of cardiac events in these patients (similar odds ratios, Table 3 ). Among patients enrolled in Western Europe, neither additional treatment benefit nor rebound effect was apparent following the discontinuation of study drug. In North American patients, a consistent trend towards a treatment benefit with eptifibatide was observed. Additional analysis revealed that this benefit was mostly due to the favourable effect of eptifibatide on patients who were still receiving study drug in the period between 72 and 96 h. In contrast, negative treatment effects were observed in the other two geographic regions, with a small disadvantage for eptifibatide in Eastern Europe and a larger, statistically significant one in Latin America. By multivariable analysis, however, odds ratios of the late treatment effect in Western Europe, Eastern Europe and North America did not differ significantly and showed neither benefit nor rebound, although a trend towards a treatment benefit was apparent in North America (Fig. 2) . The odds ratios reflecting the negative treatment effect between day 3 and 30 in Latin America were significantly different from those observed in the other regions.
Discussion
In the initial univariate PURSUIT analysis, the treatment effect appeared greater in North America than in Western Europe, while no treatment effect was apparent in Latin America and Eastern Europe [1] . However, the confidence intervals for the treatment effects in these regions were wide and overlapping. The present analysis suggests that the apparent differences in patient outcome and treatment effect can be explained largely by differences in patient characteristics and treatment strategies, and by the adjudication process.
Baseline demographics and early (<72 h) patient outcome and treatment effect
Patients enrolled in Eastern Europe were older, had a history of more severe coronary artery disease including 
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a worse angina pectoris class and heart failure, and more often exhibited ST-segment depression on the qualifying electrocardiogram. These factors are associated with a worse outcome in patients with acute coronary syndromes [8] [9] [10] [11] [12] [13] . This is reflected in this analysis by the higher rates of mortality and the combined end-point at 72 h in Eastern European patients. After correction for baseline characteristics in the multivariable analysis, Eastern Europe was no longer a significant predictor of mortality. However, differences in the combined event rate according to the Clinical Events Committee were maintained, with an increased risk in Eastern Europe as compared with Western Europe and North America. Eastern European origin was not an independent risk factor with respect to the combined outcome when more stringent criteria of infarction were applied. Therefore, the original protocol definition of myocardial infarction and the adjudication process should be considered in this context as discussed below. Furthermore, the developed multivariable models concentrated on baseline characteristics and risk factors at the moment of hospital admission. Consequently, differences between countries and regions in applied management styles and treatment strategies are post-randomization events for which it would be impossible to control for adequately. Finally, the role of chance cannot be excluded. The high mortality rate in Latin America remains an unexplained finding.
Despite differences in adverse cardiac event rates among the four geographic regions, eptifibatide showed a consistent trend towards a reduction in mortality and the composite end-point at 72 h in each region and for each definition of myocardial infarction. Although most comparisons failed to reach statistical significance, most probably due to the small number of patients per subgroup, only one exception was observed: the original assessment by the Clinical Events Committee of myocardial infarction occurring in Eastern Europe. This consistency with respect to the directionality of the treatment benefit was maintained in the multivariable analysis.
Impact of percutaneous coronary intervention
In patients with acute coronary syndromes as well as in patients with stable angina, coronary intervention is associated with a 5% to 10% myocardial infarction rate [14] [15] [16] [17] [18] [19] . Some of these infarcts can be avoided by treatment with a glycoprotein IIb/IIIa receptor blocker at the time of coronary intervention [15] [16] [17] [18] [19] [20] . The CAPTURE study demonstrated a significant reduction in adverse cardiac events before the percutaneous coronary intervention when patients with refractory unstable angina received a glycoprotein IIb/IIIa inhibitor [17, 21] . This prevention of myocardial infarction during medical therapy preceding percutaneous coronary intervention and protection from death or infarction during the procedure were also apparent in PURSUIT patients undergoing intervention during the 72 h study drug infusion period [22] . Despite the relatively small number of patients in Western Europe undergoing percutaneous coronary intervention during this timeframe as compared to North America, the pattern of benefit was remarkably similar in both regions. Recently, this pattern has also been observed in another, large clinical trial of glycoprotein IIb/IIIa inhibition in patients presenting with acute coronary syndromes without STelevation [12] . In patients undergoing percutaneous coronary intervention after discontinuation of study drug, no incremental treatment effect is to be expected and none was observed. In fact, coronary intervention in those patients was associated with an increased myocardial infarction rate.
The observed treatment effect at 30 days is thus a combination of the preventive effect during initial medical therapy and the protection by glycoprotein IIb/IIIa inhibition from thrombotic complications associated with percutaneous coronary intervention. The large number of patients in North America undergoing percutaneous coronary intervention while receiving study drug therefore enhanced the apparent treatment effect in this region. In the other regions, coronary intervention was done less frequently and mostly after discontinuation of study drug. Accordingly, in these regions, the treatment effect as observed in the original report merely reflected the effect of medical therapy without an additional effect during percutaneous coronary intervention.
The increased benefit during the medical treatment period in Western European and North American patients subsequently undergoing an early percutaneous coronary intervention, as compared with the 72 h treatment effect in the remaining patients enrolled in these regions, may reflect a patient group at higher risk of thrombotic complications. It may also reflect investigational sites with staffing and infrastructure capable of performing early coronary intervention, allowing for optimal monitoring of patients and intervening in case of signs or symptoms unfavourably affecting the patient's prognosis (e.g. recurrent ischaemia) [9] , thus optimally exploiting the beneficial effects of eptifibatide.
Late (3-30 days) patient outcome and treatment effect
In patients without cardiac complication or percutaneous coronary intervention in the first 72 h, the rate of clinical events reported between day 3 and 30 was high in all regions. This may reflect the great effort expended in this trial to measure and collect data on myocardial enzyme levels in patients with suspected ischaemic events and in those undergoing revascularization. This is supported by the fact that the high event rate was maintained when the more stringent definitions of myocardial infarction of creatine kinase(-MB) above three or five times the upper normal limit were applied. Some of the events were associated with percutaneous coronary interventions performed after discontinuation of study drug. Contrary to its relation to the 72 h outcome, geographic region was not an independent predictor of late outcome. This might suggest that the regional differences in treatment strategies and management styles mainly influence the patient's prognosis during the acute and subacute phase of the acute coronary syndrome. After discontinuation of experimental therapy no incremental treatment benefit is to be expected since platelet function recovers rapidly after the infusion of eptifibatide has been stopped. Indeed, the high event rate associated with late, unprotected coronary interventions may have diluted the actual treatment benefit. The negative treatment effects between day 3 and 30 in Eastern Europe and Latin America contributed to the absence of treatment benefit in these regions at 30 days in the initial univariate analysis. However, in the multivariable analysis there were no significant differences in treatment effect between day 3 and 30, which showed neither benefit nor rebound, among Western Europe, Eastern Europe and North America, although there was a trend towards more beneficial effect in the last region. The negative late treatment effect in Latin America is difficult to explain. However, it should be appreciated that only a very limited number of patients were enrolled in this region. Therefore, the role of chance cannot be excluded.
Impact of myocardial infarction definition and the adjudication process
Since even small, asymptomatic myocardial infarctions detected on the basis of elevated cardiac-enzyme levels in serum portend an unfavourable short-and long-term outcome [23] [24] [25] [26] [27] [28] , a sensitive definition of myocardial infarction was applied by the Clinical Events Committee: any elevation of creatine kinase-MB above the upper limit of normal was considered a myocardial infarction. Other recent studies investigating glycoprotein IIb/IIIa blockers have applied a threshold of two or three times the upper limit of normal for creatine kinase-MB or total creatine kinase as part of their definition of myocardial infarction [12, 17, 29] . The greatest regional variation in treatment effect in PURSUIT and the present analysis was apparent when the original CEC definition of myocardial infarction was applied, while these differences became smaller when more stringent definitions were applied, and disappeared when the clinical definition of myocardial infarction was used as assessed by the local investigator. This might be explained in part by the fact that creatine kinase-MB measurement was introduced for the PURSUIT study in a number of hospitals where this measurement was not part of the routine clinical practice, particularly in Eastern Europe. This may have resulted in a number of erroneous abnormal creatine kinase-MB values. Re-screening of patients with a discrepancy between investigator and CEC assessment of myocardial infarction resulted in identification of patients with spurious creatine kinase-MB elevations, most likely not related to myocardial necrosis [30] . After application of a more strict threshold for myocardial infarction, treatment effects in all regions consistently favoured eptifibatide.
Although accumulating data support the notion that even minor elevations of creatine kinase-MB are prognostically important [23] [24] [25] [26] [27] [28] , perhaps this level of elevation is too sensitive to allow detection of small treatment effects when employed in a global mega-trial, especially when faced with the realities of collecting enzyme data in regions of the world that do not typically perform these laboratory evaluations. Clearly, the inability to get reasonable creatine kinase-MB data is of concern for future global investigations unless standardization of methods (i.e. a central core laboratory) can be assured.
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These factors all bear consideration when defining criteria for the diagnosis of myocardial infarction in the context of clinical investigation and, especially, in the conduct of a large international mega-trial. The present data imply that the adjudication process and the creatine kinase methodologic problems may have had a major impact on the inter-region differences that emerged during the PURSUIT trial [30] .
Conclusion
In their attempt to reflect actual clinical practice, the PURSUIT investigators chose the large simple trial model in the real-life clinical setting without mandated additional treatment assignments to study the effects of eptifibatide. In choosing a global approach to the trial, including a broad spectrum of management styles and clinical practices from rural hospitals to major tertiary referral centres in 27 countries, the investigators took the risk of seeing treatment outcomes and effects that would differ in the various regions. The initial PURSUIT analysis observed large differences in patient outcome and treatment effect among the four geographic regions. The present analysis suggests that these apparent differences can largely be explained by differences in baseline patient characteristics and treatment strategies, particularly the use and timing of coronary intervention. The third major factor that contributed to the regional variation was the adjudication process and the methodology of myocardial infarction definition.
The present report should be considered as an explanatory analysis aiming to identify factors contributing to the geographic variations in outcome and treatment effect. In order to explore these differences which result from a complex interplay in each region between baseline characteristics, treatment strategies and results of the adjudication process as well as from the treatment interaction as a function of these factors, the 30-day end-point was subdivided into early and late outcome. The effect of losing statistical power was outweighed by the insight that was gained into the mechanisms involved in the geographic variations in patient outcome and treatment effect. Clearly, the analyses presented should be viewed with the limitations germane to subgroup analysis of randomized clinical trials [31] . Yet, the differences in baseline demographics, the adjunctive treatment strategies, and methodologic aspects of how events are determined all bear important consideration when analysing data from large international trials. The most important lesson of the present analysis is that global clinical trials should take into account these three important aspects when making observations regarding differences in patient outcome and consistency of the treatment effect across a multi-national network. 
